AorTech looks to new CEO (Chief Executive Officer) and restructure for stability
This article was originally published in Clinica
Executive Summary
AorTech is bidding to put recent disappointments behind it - trial delays for its polyurethane trileaflet heart valve and the slow progress in the deal to buy Becton Dickinson's critical care division (see Clinica No 1010, p 19) - with the appointment of a new CEO, Bill Strachan. Mr Strachan, formerly with Eli Lilly before moving to Johnson & Johnson where he spent 24 years, will be asked to "redress the fortunes" of the Bellshill, Scotland company, said chairman Eddie McDaid, who had additionally assumed CEO responsibilities pending a permanent appointee to the role.
You may also be interested in...
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.